Brief: Bio-Path Holdings Announces Clearance Of Investigational New Drug Application For Bp1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients
24/08/2021 15:19
Aug 24 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR BP1002 IN REFRACTORY/RELAPSED ACUTE MYELOID
LEUKEMIA PATIENTS
Source text for Eikon: ID:nGNXbFXpdj
Further company coverage: BPTH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia